REGN News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$81.46B

Volume

463.42K

Next Earnings

October 30th

Mkt Cap

$81.99B

Volume

463.42K

Next Earnings

October 30th

Chart Financials Earnings News About Dividends Insider Filings

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer TypesThe European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of an alternative dosing schedule for Libtayo (cemiplimab) across all approved cancer indications. The new regimen allows for extended dosing of 700 mg every six weeks after an initial 12-week treatment with 350 mg every three weeks, and optional reduction of infusion time to 15-30 minutes. The European Commission is expected to make a final decision in the coming months.GlobeNewswire Inc. · Oct 16, 2026

Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?Nektar Therapeutics (NKTR) initiated two Phase III studies (ZENITH AD-1 and ZENITH AD-2) for rezpeg in atopic dermatitis in July 2026, with top-line data expected mid-2028. The company plans Phase III studies for alopecia areata in early 2027 and expects Type I diabetes data in 2027. Rezpeg, a self-administered injection that activates regulatory T-cells, faces competition from established players like Sanofi/Regeneron's Dupixent. NKTR trades at a valuation discount to the industry with a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Oct 15, 2026

Here's Why You Should Add EYPT Stock to Your Portfolio NowEyePoint (EYPT) reported mixed results from its LUGANO wet AMD study, with Duravyu failing to meet the primary endpoint but showing encouraging secondary endpoint results. The company expects LUCIA study data in Q4 2026 and has completed enrollment in two phase III DME studies with results expected in Q4 2027. EYPT shares have declined 83.5% year-to-date despite a Zacks Rank #2 (Buy) rating.Zacks Investment Research · Oct 15, 2026

Which Pharma Stock Looks More Attractive: Sanofi or AbbVie?Sanofi and AbbVie are compared as major pharmaceutical companies with different growth drivers. Sanofi, powered by Dupixent's strong performance and newer medicines, trades at a lower valuation (7.82x forward earnings) with a 4.5% dividend yield, while AbbVie relies on Skyrizi and Rinvoq to offset Humira's decline but trades at 19.62x forward earnings with a 2.5% yield. Analysts favor Sanofi (Zacks Rank #3 Hold) over AbbVie (Rank #4 Sell) due to its attractive valuation and upgraded growth outlook.Zacks Investment Research · Oct 14, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarThe article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could potentially beat their quarterly earnings estimates. Regeneron (REGN) holds a #3 (Hold) rating with a +0.23% ESP ahead of its October 30, 2026 earnings release, while Danaher (DHR) has a #2 (Buy) rating with a +0.30% ESP before reporting on October 21, 2026. Both stocks show indicators suggesting potential positive earnings surprises.Zacks Investment Research · Oct 14, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarThe article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could beat their upcoming quarterly earnings estimates. ANI Pharmaceuticals (ANIP) has a +6.45% ESP ahead of its November 6, 2026 earnings release, while Regeneron (REGN) has a +0.23% ESP before reporting on October 30, 2026. Both stocks carry a Zacks Rank #3 (Hold) rating, and the article suggests that stocks with positive ESP combined with a Zacks Rank #3 or better have historically beaten earnings 70% of the time.Zacks Investment Research · Oct 13, 2026

Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?Regeneron (REGN) is positioned to potentially beat earnings estimates in its upcoming October 30, 2026 report. The company has a strong track record of beating estimates with an average surprise of 27.03% over the past two quarters, most recently delivering a 42.90% surprise. With a positive Earnings ESP of +1.21% and a Zacks Rank #3 (Hold), the combination suggests a high probability of another earnings beat.Zacks Investment Research · Oct 12, 2026

Why Regeneron (REGN) is a Top Value Stock for the Long-TermRegeneron (REGN), a biotechnology company focused on severe medical conditions, is highlighted as a stock to watch with a #3 (Hold) Zacks Rank and a VGM Score of B. The company features attractive valuation metrics with a forward P/E ratio of 13.47, and two analysts revised earnings estimates higher in the last 60 days, with the consensus estimate increasing to $54.90 per share for fiscal 2026.Zacks Investment Research · Oct 9, 2026

Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKDBayer announced FDA acceptance of a supplemental new drug application for Kerendia (finerenone) to treat chronic kidney disease in non-diabetic patients. The approval is based on positive phase III FIND-CKD trial data showing the drug significantly delayed kidney disease progression and reduced cardiovascular-kidney events. This expansion broadens Kerendia's addressable market and strengthens Bayer's cardiovascular and renal portfolio, with the drug already approved for diabetic CKD and heart failure in multiple markets.Zacks Investment Research · Oct 8, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTPomerantz LLP is investigating securities fraud claims against EyePoint, Inc. following the company's announcement that its Phase 3 clinical trial for DURAVYU failed to meet its primary endpoint against Regeneron's Eylea. The stock plummeted 66.98% to $4.87 per share on August 17, 2026.GlobeNewswire Inc. · Oct 6, 2026

REGNRegeneron Pharmaceuticals Inc

REGN

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any REGN yet.

Related Tickers

Earnings

Dividends

Last · Aug 18Quarterly

Amount$0.94

Yield0.47%

Annual$3.70

Mkt Cap

$81.46B

Volume

463.42K

Next Earnings

October 30th